Episealer®
-
Extremities
Prospective Episealer® Talus clinical study fully recruited
September 13, 2023 – Episurf Medical (Nasdaq: EPIS B) today announces that all patients have been recruited to a prospective…
Read More » -
Regulatory
Episurf Medical receives FDA 510(k) clearance for Episealer® Patellofemoral System
December 27, 2022- Episurf Medical (NASDAQ: EPIS B) today announces that the company has received 510(k) clearance from the US…
Read More » -
Recon
Episealer® Patellofemoral System – planned 510(k) submission in Q4 2021
FRI, FEB 19, 2021 08:00 CET Episurf Medical (Nasdaq: EPIS B) today announces that the company intends to submit a…
Read More » -
Recon
Positive results from follow-up of 30 patients in a Swedish multicentre clinical trial of the Episealer® Knee implant
Episurf Medical (Nasdaq: EPIS B) March 8, 2020 – Today announces that results from a clinical study with follow-up of…
Read More » -
Hospitals
Episurf Medical has received initial feedback from the US FDA on the IDE application for the Episealer® knee implant
MON, JUL 30, 2018 08:30 CET Episurf Medical (NASDAQ: EPIS B) today announces that the company has received initial feedback…
Read More » -
Extremities
Episurf Medical in the final stages of development of an ankle implant
FEB 14, 2018 With three Episealer® knee implant products currently approved and on the market in Europe, Episurf Medical (NASDAQ:…
Read More »